CN103251669B - Anti-hepatic fibrosis drug composite - Google Patents
Anti-hepatic fibrosis drug composite Download PDFInfo
- Publication number
- CN103251669B CN103251669B CN201310194381.7A CN201310194381A CN103251669B CN 103251669 B CN103251669 B CN 103251669B CN 201310194381 A CN201310194381 A CN 201310194381A CN 103251669 B CN103251669 B CN 103251669B
- Authority
- CN
- China
- Prior art keywords
- hepatic fibrosis
- treatment
- liver
- blood
- hepatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an anti-hepatic fibrosis drug composite. The anti-hepatic fibrosis drug composite is characterized by comprising the following crude drugs in parts by weight: 5-15 parts of artemisia anomala, 10-20 parts of geranium wilfordii, 1-5 parts of leeches and 1-5 parts of Zhechong. The anti-hepatic fibrosis drug composite disclosed by the invention can be used for preparing the artemisia anomala, the geranium wilfordii, the leeches and the zhechong into a compound according to a traditional Chinese medicine theory, achieves the purpose of anti-hepatic fibrosis through the synergistic action of the drugs on the aspects of anti-inflammation, anti-necrosis, hepatic cells protection, and the like and has the advantages of low price and easiness for popularization.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of anti-hepatic fibrosis, be specifically related to a kind of Chinese medicine compound of eutherapeutic anti-hepatic fibrosis.
Background technology
Hepatic fibrosis refers to by connective tissue paraplasm in liver due to various virulence factors, causes the pathological process that in liver, diffusivity extracellular matrix excessively precipitates.It is not an independently disease, and many chronic hepatic diseases all can cause hepatic fibrosis.China is the district occurred frequently that viral hepatitis is popular, viral hepatitis be the commonly encountered diseases that causes hepatic fibrosis and liver cirrhosis because of, chronic hepatitis patient reaches tens million of, wherein has an appointment again 1/10 ~ 1/3 can develop into liver cirrhosis.Hepatic fibrosis is the pathologic basis that the various causes of disease cause liver cirrhosis.In recent years, along with the developing rapidly and applying of Medical Molecular Biology, the understanding of hepatic fibrosis is deepened continuously, for treatment provides many possible approach.Think at present, hepatic fibrosis is reversible, by fibrosis, is treated and can be made degree of hepatic fibrosis obviously alleviate.And most treatments are at present still in the experimentation stage.The formation of hepatic fibrosis and development are extremely complicated processes; in the treatment of hepatic fibrosis, multiple treatment use in conjunction is extremely important, mainly comprises etiological treatment, hepatocyte protection and regenerative therapy, the immunization therapy of hepatic fibrosis, the activation suppression therapy of hepatic stellate cell, the methods such as adjustment for the treatment of of extracellular matrix.Chinese medicine is demonstrating obvious advantage aspect intervention hepatic fibrosis.The method for the treatment of by Chinese herbs hepatic fibrosis has single medicinal material treatment and compound of Chinese medicine.Single medicinal material has Radix Salviae Miltiorrhizae, the Radix Astragali, Radix Et Rhizoma Rhei, Cordyceps, Rhizoma Curcumae etc.The more Chinese medicine compound of research has compound recipe 861 mixture, stilbene art granule, Fuzheng Huayu 319 Recipe, the red diisopropylamine dichloroacetate of the Chinese, Herba Sidae Rhombifoliae soup, biejiajian pills etc. at present.Chinese medicine compound has pharmacology's advantage of multicomponent, too many levels, multi-level, many target spots, and its treatment hepatic fibrosis curative effect is more remarkable.
Summary of the invention
The invention provides a kind of pharmaceutical composition of anti-hepatic fibrosis, by the pharmacological action approach of multicomponent, too many levels, multi-level, many target spots, reach the object of anti-hepatic fibrosis.
For achieving the above object, the technical solution used in the present invention is: a kind of pharmaceutical composition of anti-hepatic fibrosis, is comprised of the crude drug of following parts by weight:
Herba Artemisiae Anomalae 5-15 part;
Herba Erodii 10-20 part;
Hirudo 1-5 part;
Female ground beetle 1-5 part.
Related content in technique scheme is explained as follows:
In such scheme, in described pharmaceutical composition, the good amount ranges of each crude drug is:
Herba Artemisiae Anomalae 7-13 part;
Herba Erodii 12-18 part;
Hirudo 2-5 part;
Female ground beetle 2-5 part.
Therapeutic mechanism of the present invention is: hepatic fibrosis belongs to the category of traditional Chinese medical science liver blood stasis, and it is long that this type of disease mostly is the course of disease, and more, prolonged illness consumes impairment of QI blood to touching difficulty, internal injury Liver and kidney, and deficiency-heat is gradually raw, and healthy energy is difficult multiple, and its pathogenesis mostly is qi depression to blood stasis.Pharmaceutical composition of the present invention is from Fibrotic main pathomechanism incision, select Herba Artemisiae Anomalae, Herba Erodii, Hirudo, female ground beetle four taste activating blood and removing stasis drugs to form, wherein Herba Erodii He female ground beetle have dredge through, invigorate blood circulation, the effect of blood stasis dispelling, Herba Artemisiae Anomalae and Hirudo can strengthen the effect of promoting blood circulation to remove obstruction in the collateral, improve hepatic tissue microcirculation, that is to say that Herba Artemisiae Anomalae, Herba Erodii, Hirudo, female ground beetle four taste activating blood and removing stasis drug synergism can strengthen the curative effect of anti-hepatic fibrosis.Confirm after deliberation, it can make patients with liver fibrosis Serum hyaluronic acid (HA), layer mucoprotein (LN), type Ⅳ collagen (IV-C) content significantly decline, and curative effect is better.According to theory of Chinese medical science, Herba Artemisiae Anomalae, Herba Erodii, Hirudo, female ground beetle are made to compound recipe, by the aspect synergism such as antiinflammatory, necrosis and protection hepatocyte of medicine; the hypertrophy that suppresses fat-storing cell; reduce the synthetic of collagen, promote liver reparation, reach the object of anti-hepatic fibrosis.
In pharmaceutical composition of the present invention, the pharmacology of each Chinese medicine ingredients and the property of medicine are as follows:
Herba Artemisiae Anomalae: hardship.Temperature, GUIXIN, liver, spleen channel.Effect removing blood stasis stimulates the menstrual flow, dispersing cold for relieving pain, promoting digestion and removing stagnation.< < book on Chinese herbal medicine remittance > > records " Herba Artemisiae Anomalae, start with few the moon, meridian of Foot-TAI YIN.Stimulate the menstrual flow and help the side of removing blood stasis, the agent of loose strongly fragrant auxiliary pungent perfume (or spice).Press the celestial agent of Herba Artemisiae Anomalae removing blood stasis also, its property is apt to away, specially enters blood system, bitter in the mouth GUIXIN, and warm property is suitable with spleen again, therefore two enter.The main blood of the lid heart, spleen is wrapped up in blood, so specially treat blood disorder also." can be used for Zhi Liao lumps in the chest and abdomen, jaundice due to damp-heat, edema abdominal distention.Herba Artemisiae Anomalae has acceleration blood circulation, removes smooth muscle spasm, promotes hemagglutinative function; Decocting liquid can increase Cavia porcellus and fill with arteries and veins flow, and anoxia in mice model is had to obvious oxygen lack resistant function.
Herba Erodii: pungent, bitter, flat.Return liver,kidney,spleen warp.Cure mainly wind-damp dispelling, the meridian dredging, antidiarrheal profit.For rheumatic arthralgia, numbness contracture, muscles and bones is ached, dysentery.Herba Erodii have dredge through, invigorate blood circulation, the effect of heat clearing away, removing toxic substances, dampness removing, damp and hot, the stasis of blood that occurs for chronic hepatitis patient is stagnant pents up, qi and blood disorder, has good therapeutical effect.
Hirudo: salty, bitter, flat.Slightly poisonous.Return Liver Channel.Removing blood stasis stimulates the menstrual flow, Zhu Yu Xiao Disorder.< < Sheng Nong's herbal classic > > records: " main by stagnant blood, blood stasis, the moon closes, removing blood stasis, loss of fecundity, dredging water passages." chemical composition: mainly containing protein.In saliva, contain hirudin, also contain heparin, antithromboxin and H-subst.Blood coagulation resisting function: the platelet aggregation to adenosine diphosphate (ADP) (ADP) induction all has significant inhibitory action, and can reduce whole blood contrast viscosity and plasma viscosity, shortens erythrocyte electrophoretic time; Hirudo extract, hirudin have obvious inhibitory action to platelet aggregation, suppress rat thrombus in vivo and form, and disseminated inravascular coagulation is had to good therapeutical effect.The thrombosis that hirudin causes bacterial endotoxin has preventive effect, and can reduce mortality rate; Improve microcirculation; Hirudo has obvious reducing effect to the cholesterol of experimental hyperlipidemia and triglyceride.Hirudin has inhibitory action to tumor cell, and liver cancer growth is had to certain inhibitory action.Because Hirudo has high anticoagulation, thereby be conducive to anticarcinogen and immunologically competent cell and immerse cancerous tissue and kill and wound cancerous cell.
Female ground beetle: female ground beetle is strong activating blood and removing stasis drug, can play and improve liver microcirculation, improves liver blood and oxygen supply.Modern medicine study thinks, syndrome of blood stasis is present in the whole pathological process of chronic hepatopathy, in close relations with hepatic fibrosis.
The invention has the beneficial effects as follows: formula of the present invention has good effect of anti hepatic fibrosis, by the pharmacological action approach of multicomponent, too many levels, multi-level, many target spots, reach the object of anti-hepatic fibrosis, there is at a low price, be easy to the advantage promoted.
The specific embodiment
Below in conjunction with embodiment, the invention will be further described:
Embodiment mono-: a kind of pharmaceutical composition of anti-hepatic fibrosis
Pharmaceutical composition prescription is comprised of the crude drug of following weight:
Herba Artemisiae Anomalae 10g;
Herba Erodii 15g;
Hirudo 3g;
Female ground beetle 3g.
Embodiment bis-: a kind of pharmaceutical composition of anti-hepatic fibrosis
Pharmaceutical composition prescription is comprised of the crude drug of following weight:
Herba Artemisiae Anomalae 10g;
Herba Erodii 20g;
Hirudo 2g;
Female ground beetle 2g.
Embodiment tri-: a kind of pharmaceutical composition of anti-hepatic fibrosis
Pharmaceutical composition prescription is comprised of the crude drug of following weight:
Herba Artemisiae Anomalae 15g;
Herba Erodii 20g;
Hirudo 5g;
Female ground beetle 5g.
Embodiment tetra-: a kind of pharmaceutical composition of anti-hepatic fibrosis
Pharmaceutical composition prescription is comprised of the crude drug of following weight:
Herba Artemisiae Anomalae 14g;
Herba Erodii 36g;
Hirudo 4g;
Female ground beetle 4g.
Embodiment five: a kind of pharmaceutical composition of anti-hepatic fibrosis
Pharmaceutical composition prescription is comprised of the crude drug of following weight:
Herba Artemisiae Anomalae 13g;
Herba Erodii 12g;
Hirudo 2g;
Female ground beetle 2g.
Clinical practice example: adopt formula of the present invention to make oral liquid formulations, above and compensatory phase patient 60 examples of liver cirrhosis for the treatment of chronic hepatitis moderate, and to take 60 examples that Herba Sidae Rhombifoliae soup adds essentiale capsule for treating in contrast, obtain satisfactory effect, be now reported as follows:
1. clinical data: select the above and compensatory phase patient of liver cirrhosis of chronic hepatitis moderate totally 120 examples, be the outpatient of the court, be divided at random treatment group and matched group.Treatment group 60 examples, moderate chronic hepatitis 40 examples wherein, severe 10 examples, compensatory phase patient 10 examples of liver cirrhosis; Male 50 examples wherein, female's 10 examples, age 19-63 year, course of disease 2-15; Matched group 60 examples, situation and treatment group approach, and two groups of clinical data no significant differences, have good comparability.Selected case Serum hyaluronic acid (HA) familial combined hyperlipidemia collagen all shows extremely.
2. the diagnostic criteria of hepatic fibrosis:
2.1 liver biopsy pathology check: being still the goldstandard of diagnosing liver fibrosis, is the important evidence of clarifying a diagnosis, weighing course inflammatory activity degree, fibrosis and judge curative effect of medication.Generally adopt at present semiquantitative scoring system.But, due to hepatic fibrosis skewness in liver, and liver puncture organize only account for 50,000 of full liver/, can cause Error Diagnostics.Therefore emphasize liver biopsy specimen at least 15 mm, and comprise 6 above portal areas.
2.2 imaging examinations: B ultrasonic has good dependency to liver surface, liver echo, hepatic vein, liver edge and 5 parameters of spleen area and Liver Fibrosis Stages, but to the more difficult differentiation of 1 ~ 3 phase.Also someone thinks that the degree of the maximum isoparametric change of clino-diagonal of main portal vein, portal vein blood flow parameter per minute, spleen thickness, splenic vein width and right lobe of liver and hepatic fibrosis has good dependency.
2.3 biochemical detections: Serum hyaluronic acid (HA), laminin，LN (LN), III procollagen type (PCIII), type Ⅳ collagen (CIV) can reflect degree of hepatic fibrosis, particularly HA and PCIII are the highest to the value of Early hepatic fibrosis, are also subject to the impact of inflammation degree simultaneously.
2.4 color doppler ultrasonography contribute to evaluate the degree of hepatic fibrosis, because during hepatic fibrosis, hepatic artery blood flow speed increases, portal vein Flow Velocity slows down, therefore the ratio of the two can more fully reflect that the hemodynamics of hepatic fibrosis changes, and is better than measuring merely the detection of portal vein flow velocity or the change of hepatic vein frequency spectrum.
3. Therapeutic Method: treatment group is taken " easing the affected liver oral liquid " (every 10ml is containing Herba Artemisiae Anomalae crude drug 10g, Herba Erodii crude drug 15g, Hirudo crude drug 3g, female ground beetle crude drug 3g), each oral 10ml, every day three times, serveing on 3 months is a course for the treatment of; Matched group is taken Herba Sidae Rhombifoliae soup and is added essentiale capsule.Herba Sidae Rhombifoliae soup forms: Radix Bupleuri 10g, Radix Scutellariae 10g, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10g, Radix Codonopsis 10g, Rhizoma Zingiberis Recens 3g, Radix Glycyrrhizae 5g, every day, potion was decocted secondary clothes.Essentiale every day three times, each two.All take for two groups and treat 3 months as a course for the treatment of, after 2 courses for the treatment of, add up therapeutic effect.
4. observation index and method: observe Serum hyaluronic acid (HA), type Ⅳ collagen (C IV), the laminin，LN (LN) of hepatic fibrosis serum in checking, all adopt radioimmunology, test kit is provided by Shanghai INM biotechnology center.Alanine aminotransferase (ALT) and gamma Globulin (γ-G) detect according to general routine biochemistry inspection.MethodsThe cases enrolled is done comprehensive health check-up before dispensing, and gets blood 10ml, except looking into liver function and hepatitis b virus marker, isolates 3ml serum frozen in-80 ℃ of cryogenic refrigerators, after treatment finishes, by unification, detects hepatic fibrosis index.
5. therapeutic outcome
5.1 hepatic fibrosis indexs: every measured value of normal person and healthy blood donation personnel is respectively HA 57 ± 27ng/ml, C IV 49.77 ± 15.0ug/L, LN 115.7 ± 17.3ng/ml, before and after treatment, two groups of hepatic fibrosis index levels relatively refer to table 1.
Before and after table 1 liang group treatment, HA, C IV, LN level change (X ± S, i.e. mean+SD)
As can be seen from Table 1, the HA level of matched group is obvious decline (P < 0.05) before treating after treatment, the C IV level of matched group is obvious decline (P < 0.05) before treating after treatment, the HA level for the treatment of group is obvious decline (P < 0.01) before treating after treatment, the C IV level for the treatment of group is obvious decline (P < 0.01) before treating after treatment, the LN level for the treatment of group is obvious decline (P < 0.05) before treating after treatment, the HA level for the treatment of group after treatment compared with obviously decline after treatment of control group (P < 0.05), the C IV level for the treatment of group after treatment compared with obviously decline after treatment of control group (P < 0.05).In a word, easing the affected liver oral liquid can significantly reduce HA in serum, LN, C IV level, and Herba Sidae Rhombifoliae soup adds essentiale, also can significantly reduce HA, C IV level.
5.2 impacts on alanine aminotransferase (ALT) and gamma Globulin (γ-G), the results are shown in Table 2.
The variation (X ± S) of ALT and γ-G before and after table 2 liang group treatment
| ? | Case load | ALT | ALT | Case load | γ-G | γ-G |
| ? | n | Before treatment | After treatment | n | Before treatment | After treatment |
| Treatment group | 60 | 193.45±35.07 | 78.63±20.46 | 60 | 31.93±15.17 | 20.27±8.32 |
| Matched group | 60 | 190.05±25.86 | 94.39±23.14 | 60 | 32.23±10.75 | 24.42±7.61 |
As can be seen from Table 2, the ALT content for the treatment of group obviously reduces (P < 0.01) before treatment after treatment, γ-G content for the treatment of group obviously reduces (P < 0.05) before treatment after treatment, being treatment group after Rougan Mixture treatment, ALT and γ-G content obviously reduce, and there is very significant (P < 0.01) and significance (P < 0.05), but with matched group comparison, no significant difference, illustrate two groups all effective.
Disease situation of change before and after 5.3 treatments.The sings and symptomses such as tired weak, the vexed poor appetite of gastral cavity of two groups of patient's bodies, side of body rib dull pain, dizzy order are puckery, abdominal distention loose stool, the lower mass in the abdomen (hepatosplenomegaly) of the side of body, the body of the tongue stasis of blood purple, liver palm, spider angioma all have improvement in various degree, no significant difference between two groups (P>0.05) after treating.
Above-described embodiment is only explanation technical conceive of the present invention and feature, and its object is to allow person skilled in the art can understand content of the present invention and implement according to this, can not limit the scope of the invention with this.All equivalences that spirit is done according to the present invention change or modify, within all should being encompassed in protection scope of the present invention.
Claims (2)
1. a pharmaceutical composition for anti-hepatic fibrosis, is characterized in that: the crude drug by following parts by weight forms:
Herba Artemisiae Anomalae 5-15 part;
Herba Erodii 10-20 part;
Hirudo 1-5 part;
Female ground beetle 1-5 part.
2. the pharmaceutical composition of anti-hepatic fibrosis according to claim 1, is characterized in that: the crude drug by following parts by weight forms:
Herba Artemisiae Anomalae 7-13 part;
Herba Erodii 12-18 part;
Hirudo 2-5 part;
Female ground beetle 2-5 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310194381.7A CN103251669B (en) | 2013-05-23 | 2013-05-23 | Anti-hepatic fibrosis drug composite |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310194381.7A CN103251669B (en) | 2013-05-23 | 2013-05-23 | Anti-hepatic fibrosis drug composite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103251669A CN103251669A (en) | 2013-08-21 |
| CN103251669B true CN103251669B (en) | 2014-07-23 |
Family
ID=48956102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310194381.7A Active CN103251669B (en) | 2013-05-23 | 2013-05-23 | Anti-hepatic fibrosis drug composite |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103251669B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058765A (en) * | 2010-11-19 | 2011-05-18 | 天津太平洋制药有限公司 | Chinese medicine preparation for treating cirrhosis and preparation method thereof |
| CN102218104A (en) * | 2010-04-15 | 2011-10-19 | 张立中 | Traditional Chinese medicine preparation for preventing liver fibrosis and treating liver cirrhosis |
-
2013
- 2013-05-23 CN CN201310194381.7A patent/CN103251669B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102218104A (en) * | 2010-04-15 | 2011-10-19 | 张立中 | Traditional Chinese medicine preparation for preventing liver fibrosis and treating liver cirrhosis |
| CN102058765A (en) * | 2010-11-19 | 2011-05-18 | 天津太平洋制药有限公司 | Chinese medicine preparation for treating cirrhosis and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| 刘翔.江一平治疗慢性肝炎肝纤维化经验.《江西中医药》.2007,第38卷(第4期),第8-9页. |
| 单味中药抗肝纤维化机制研究概述;李川等;《环球中医药》;20121031;第5卷(第10期);第791页左栏第1段 * |
| 岳煜等.肝纤维化中医药研究进展.《中医学报》.2010,第25卷(第6期),第1243-1245页. |
| 李川等.单味中药抗肝纤维化机制研究概述.《环球中医药》.2012,第5卷(第10期),第789-792页. |
| 江一平治疗慢性肝炎肝纤维化经验;刘翔;《江西中医药》;20070430;第38卷(第4期);第9页左栏第2段和右栏第1段 * |
| 肝纤维化中医药研究进展;岳煜等;《中医学报》;20101130;第25卷(第6期);第1243页右栏第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103251669A (en) | 2013-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105535694A (en) | Traditional Chinese medicine composition for treating hyperuricemia | |
| CN102688420B (en) | Traditional Chinese medicine decoction for treating psoriasis | |
| CN103751562B (en) | A kind of Chinese medicine for the treatment of calculus | |
| CN104825944A (en) | Drug for treating blood-heat psoriasis and preparation method thereof | |
| CN104491733A (en) | Application of traditional Chinese medicine preparation in preparation of medicines for treating anemia, deficiency of vital energy and debilitation | |
| CN103341092A (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN103041241B (en) | Compound psoriasis arthropathica removal decoction | |
| CN103251669B (en) | Anti-hepatic fibrosis drug composite | |
| CN104288296A (en) | Traditional Chinese medicine composition for treating cholelithiasis | |
| CN103705846A (en) | Traditional Chinese medicine preparation for treating ovarian cyst | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN104825925A (en) | Traditional Chinese medicine for treating leukorrhagia | |
| CN104840865A (en) | Traditional Chinese medicine preparation for treating gouty arthritis | |
| CN104274544B (en) | A kind of Chinese medicine decoction treating hepatocarcinoma | |
| CN102327435A (en) | Traditional Chinese herb preparation for treating gout | |
| CN103721019B (en) | A kind of Chinese medicine composition improving rheumatoid arthritis | |
| Jinghui et al. | The prescription rule analysis of the new theory on spleen dampness syndrome by academician TONG Xiaolin | |
| CN105213975A (en) | A kind of pharmaceutical composition and application thereof for the treatment of liver cirrhosis | |
| CN105687865A (en) | Traditional Chinese medicine composition for treating stranguria | |
| CN105327295A (en) | Capsules for treating hepatitis and preparing method thereof | |
| CN1294979C (en) | Chinese traditional medicine for treating cholecystitis | |
| CN104587416A (en) | Traditional Chinese medicinal composition for treating early hepatocirrhosis | |
| CN1349815A (en) | Prepn of rheumatism treating medicine powder | |
| CN103520574A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN102302623A (en) | Traditional Chinese medicinal preparation for treating neonatal hepatitis syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |